Search results
Results from the WOW.Com Content Network
Treatment of generalized pustular psoriasis (GPP) in people aged twelve years of age and older and weighing at least 40 kg [2] Tarlatamab: Treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy [2] Tirzepatide: Eli Lilly
As ovarian cancer is rarely symptomatic until an advanced stage, [42] regular pre-emptive screening is a particularly important tool for avoiding the late stage at which most patients present. However, A 2011 US study found that transvaginal ultrasound and cancer marker CA125 screening did not reduce ovarian cancer mortality. [43]
A breakthrough therapy designation can be assigned to a drug if "it is a drug which is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition" and if the preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as ...
AbbVie has pinned its hopes on Elahere, which it acquired as part of a $10 billion buyout of ImmunoGen in November last year, as its top-selling arthritis treatment Humira faces newer rivals.
Specific follow-up depends on, for example, the type and stage of ovarian cancer, the treatment, and the presence of any symptoms. Usually, a check-up appointment is made about every 2 to 3 months initially, followed by twice per year for up to 5 years. [122] For epithelial ovarian cancers, the most common test upon follow-up is CA-125 level.
According to research, most ovarian cancers start at the epithelial layer which is the lining of the ovary. Within this epithelial group ovarian clear-cell carcinoma makes up 5–10%. It was recognized as a separate category of ovarian cancer by the World Health Organization in 1973. Its incidence rate differs across various ethnic groups.
English: An interview on Open Access to research journals with Dr. Francis S. Collins, Director of the National Institutes of Health, and Jack Andraka, the 16-year-old inventor of a breakthrough cancer diagnostic and winner of the 2012 Intel International Science and Engineering Fair. Presented by the Right to Research Coalition, with support ...
The mainstay of treatment is surgery to remove the residual ovarian tissue. Women with ORS with a pelvic mass should have appropriate evaluation for malignancy ( cancer ). Hormonal therapy to suppress ovarian function is an alternative treatment for those who refuse surgery, or those who are not candidates for surgery. [ 3 ]